Across 3 days of carefully curated sessions, you can look forward to gathering with over 100 of the leading C-Level executives and KOLs in the neoantigen field from the likes of BioNTech, Gritstone, Advaxis, Genocea, Treos Bio to explore the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens for enhanced anti-tumor responses.

Promising novel clinical data, interactive discussion, and engaging networking opportunities, you will leave the Neoantigen Based Therapies Summit equipped with new collaborations across pharma, biotech, and academia, and advanced knowledge on how to supercharge vaccine and cell immunotherapies for solid tumors and beyond.

You can’t afford to miss the Neoantigen Based Therapies Summit as we bring you an abundance of new data, innovative insights, and valuable lessons learned on how to drive meaningful clinical responses.